Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Diversity of Antigen Receptors

Diversity of Antigen Receptors

Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells in advanced multiple myeloma.

Blood·2026

Same author

Intravesical mesothelin-based CAR T cells targeting MUC16 effectively control bladder cancer in preclinical models.

The Journal of experimental medicine·2026

Same author

Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models.

Blood cancer discovery·2026

Same author

IL-36γ armored CAR T cells reprogram neutrophils to induce endogenous antitumor immunity.

Cancer cell·2025

Same author

CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia.

Blood·2025

Same author

Addendum: Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase.

Nature medicine·2025

Search research articles

Related Experiment Video

Updated: Mar 23, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Driving CAR T-cells forward.

Hollie J Jackson¹, Sarwish Rafiq¹, Renier J Brentjens^1,2,3

¹Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USA.

Nature Reviews. Clinical Oncology

|March 23, 2016

Summary

Chimeric antigen receptor (CAR) T-cell therapy shows promise for treating cancers. Ongoing trials explore new targets and strategies to improve CAR T-cell efficacy and safety in patients.

More Related Videos

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

Related Experiment Videos

Last Updated: Mar 23, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

Area of Science:

Immunology
Oncology
Biotechnology

Background:

Chimeric antigen receptors (CARs) engineered on T cells redirect T-cell specificity.
Early CAR T-cell trials yielded modest results, but CD19-targeted therapies for B-cell malignancies show significant promise.
This has spurred enthusiasm and further research into CAR T-cell therapy.

Purpose of the Study:

To review current clinical trials of CAR T-cell therapy.
To discuss novel CAR designs and targets for hematological and solid tumors.
To present strategies for enhancing antitumour efficacy and safety of CAR T-cell therapy.

Main Methods:

Review of ongoing clinical trials with translational applications.
Analysis of CAR T-cell designs and targeting strategies.
Discussion of methods to improve therapeutic outcomes.

Main Results:

CD19-targeted CAR T-cell therapy has demonstrated impressive outcomes in B-cell malignancies.
Ongoing trials are investigating novel targets for both hematological and solid tumors.
Strategies to improve efficacy and safety are being actively explored.

Conclusions:

CAR T-cell therapy is a rapidly advancing field with significant potential.
Further research and clinical trials are crucial for optimizing CAR T-cell treatments.
Improving antitumour efficacy and patient safety are key priorities for future development.